DB

David Brooks

No bio yet


Org chart


Teams

This person is not in any teams


Offices

This person is not in any offices


Boston Immune Technologies & Therapeutics

BITT has developed a platform for targeting the tumor necrosis factor receptor 2 (TNFR2) oncogene and the potent population of TNFR2 Tregs in the tumor microenvironment.


Employees

1-10

Links